This second best practice review examines five series of common primary care questions in laboratory medicine: (1) laboratory testing for allergy, (2) diagnosis and monitoring of menopause, (3) the use of urine cytology, (4) the usefulness of the erythrocyte sedimentation rate, and (5) the investigation of possible urinary tract infection. The review is presented in a question–answer format. The recommendations represent a précis of guidance found using a standardised literature search of national and international guidance notes, consensus statements, health policy documents, and evidence based medicine reviews, supplemented by MEDLINE EMBASE searches to identify relevant primary research documents. They are standards but form a guide to be set in the clinical context. Most are consensus rather than evidence based. They will be updated periodically to take account of new information.

**When should I request total IgE in general practice?**

We recommend that there is very limited need for this test in general practice, except as an adjunct to the diagnoses listed below.

- IgE concentrations can be increased in non-allergic states such as parasite infections, Churg-Strauss vasculitis, certain immune deficiencies such as the hyper-IgE syndrome, IgE myeloma, Hodgkin lymphoma, and atopic dermatitis. These are all rare conditions, usually diagnosed in secondary care, and the measurement of IgE is not crucial to the diagnosis.
- Total IgE alone can neither confirm nor exclude allergy: increased concentrations may suggest an atopic state, but normal or low values do not exclude allergy. Normal or low IgE concentrations also cannot be used as a prescreening test for radioallergosorbent testing (RAST).
- Therefore, it is inappropriate to request total IgE in isolation from general practice in this context.

**GMS contract indicator: none.**

**When should I request allergen specific IgE (RAST)?**

We recommend allergen specific IgE measurement in the presence of the clinical suspicion of type 1 IgE mediated hypersensitivity/allergy, principally for inhaled antigens. There is no need to request total IgE when requesting RAST.

- Seasonal rhinoconjunctivitis (hay fever).
- Perennial rhinoconjunctivitis.
- Anaphylaxis.
- Acute urticaria with angio-oedema.
- Food allergy (with suspected trigger).
- Drug allergy (with suspected trigger).
- Suspected allergy to insect stings.

There is limited consensus guidance on the use of RAST testing in particular, as distinct from allergy testing in general, and the guidance above is drawn principally from review articles and by extrapolation from clinical studies.

**Abbreviations:** AUA, American Urological Association; FSH, follicle stimulating hormone; GMS, General Medical Services; MH, microscopic haematuria; RAST, radioallergosorbent testing; UTI, urinary tract infection
RAST refers to one of the first tests used to test allergen specific IgE, which is no longer in use; a more appropriate name is allergen specific IgE testing. It is used as a more accessible or more convenient alternative to skin prick testing. It is only useful for assessing type I IgE mediated reactions (immediate hypersensitivity); RAST tests are therefore not useful for assessing pseudo-allergic reactions that are not mediated by IgE (such as non-allergic food intolerance; reactions to radiocontrast media, morphine, and aspirin; physical urticarias, etc.). Angio-oedema without urticaria is usually not an IgE mediated allergic reaction. RAST testing and skin prick testing are of little value in chronic urticaria, which is usually not caused by IgE dependent mechanisms.

RAST tests must be requested for a specified antigen based on clinical history. They are of no benefit as screening tests without specified antigens. It follows from this that requests should not be for widespread antigen screening. Test results must be interpreted in conjunction with clinical findings. The specificity and sensitivity of RAST results vary for the different allergens tested (for example, poor for fruits and vegetables). Overall, RAST tests have relatively low sensitivity and can be negative in the presence of allergy.

In addition, adverse reactions to foods are IgE mediated allergies in only about a third of patients. Therefore, RAST tests are of limited value in this situation. It follows from this that RAST testing in food intolerance is unlikely to be helpful, and we recommend that it is used only in the initial investigation of severe acute food intolerance reactions where a specific food is suspected.

The efficacy of unconventional/alternative allergy testing has not been confirmed, and can neither substitute nor complement RAST and other classic allergy tests. Therefore, these tests are not recommended.

GMS contract indicator: none.

INVESTIGATION OF THE MENOPAUSE (RG AND WSAS)

The documents found are consistent in their recommendations for laboratory testing in the menopause. The clearest message from these documents is that hormone measurements have no role in diagnosing menopause in patients of menopausal age with typical symptoms, or in monitoring patients on oral hormone replacement. They identify specific areas for their use. These answers do not specifically address premature ovarian failure, which will be examined in later questions on subfertility.

When should I request tests for menopause?

We recommend that hormone assays are of no value in investigating women over 45 years old with typical menopausal symptoms. Follicle stimulating hormone (FSH) assays in suspected premature ovarian failure or an atypical menopausal presentation are limited to indicating that ovarian failure may have occurred.

In younger women presenting with possible early menopause (<45 years) or premature ovarian failure (<40 years) FSH assays can be useful. The finding of two separate FSH results of >40 IU/litre taken four to eight weeks apart suggests ovarian failure. One guideline recommends testing oestrogen and FSH. However, premenopausal results cannot exclude ovarian failure as a diagnosis, and although fertility declines greatly in association with FSH values over 25 IU/litre, they offer no guarantee of infertility, and advice to discontinue contraception is based on the length of amenorrhoea (see below). Population ranges of FSH even 10 years after clinical onset of menopause are also extremely wide, and can depend on assay method. Hormone tests are also thought to play no role in deciding on the type of hormone replacement therapy for symptomatic menopause if being considered.

Two other patient groups who may benefit from FSH assays are those on the oral contraceptive and those who have had a hysterectomy. In both cases, the biological marker of oligomenorrhea as an indicator of ovarian failure is not applicable. In women coming off oral contraception, alternative contraception should be used for one year of amenorrhoea in those >50 years old and for two years in those <50 years old.

There is considerable unnecessary requesting of FSH assays in women over 45 years with menopausal symptoms. This could be greatly reduced by the use of requesting guidelines agreed between the laboratory and requesting clinicians.

GMS contract indicator: none.

What tests are required to monitor women on hormone replacement therapy?

We do not recommend that FSH or oestrogen should be measured to monitor patients on hormone replacement therapy except in the following situations:

- Questionable absorption.
- Before replacement of oestrogen implants.
- Questionable compliance.

Women should be assessed only on clinical response where treatment is given for symptomatic relief and treatment altered where appropriate. The assay of oestrogen may occasionally be of value to establish its adequate absorption in women where poor absorption is suspected. Measurements have also been recommended in women with an oestrogen implant before implant replacement to ensure that no accumulation of oestrogen has occurred to avoid supraphysiological concentrations and possible tachypnoeal. Neither FSH nor oestrogen measurement is recommended in women receiving oral hormone replacement, because results are difficult to interpret meaningfully, and vary depending on oestrogen type. There is a theoretical case for measuring oestradiol in patients with persisting symptoms if poor treatment compliance is suspected.

GMS contract indicator: none.

ERYTHROCYTESEDIMENTATION RATE (EL AND DB)

The erythrocyte sedimentation rate (ESR), often used as a non-specific screen for illness, causes interpretation difficulties because of various factors that influence values and can lead to further investigations. This question examines situations when use of the test is and is not recommended, based on a range of guidelines and primary studies of test utility. It does not attempt to compare its usefulness with
that of plasma viscosity, which is used as an alternative test in many situations.

When should I request an ESR?

We recommend that ESR should be used:

- To evaluate patients with unexplained symptoms or a deterioration of health status when:
  - inflammatory, neoplastic, or infectious disease is suspected and
  - a specific diagnosis is not made effectively by other means.
- To monitor the activity of giant cell arteritis, polymyalgia rheumatica, and inflammatory arthritis.

There is no evidence to support the use of the ESR in asymptomatic individuals and this test should not be appended to “routine” investigations.

The ESR is a relatively non-specific test that is frequently ordered during the diagnosis and monitoring of disease. A variety of factors influence the sedimentation rate. Disease related factors that may affect the ESR include plasma immunoglobulin and fibrinogen concentrations, and the presence and degree of anaemia. Factors unrelated to disease processes that may affect ESR values include age, sex, and drug treatment.

A simple rule for calculating the normal ESR with age is:

\[(\text{age} + 10) \div 2 \text{ for women, } \text{age} + 2 \div 2 \text{ for men.}\]

There is no evidence to support the use of the ESR in asymptomatic individuals. Raised ESR values are found in a variety of pathological states. If the clinical history and physical findings are suggestive of specific disease processes, other investigations are usually more appropriate. For instance, although individuals with an ESR greater than 100 mm/hour are probably suffering from serious systemic disease, the presence of such diseases (malignancy, infection, cirrhosis, collagen disease, etc.) is generally detectable by clinical examination and history. However, the ESR may provide useful information when:

- Used as a diagnostic criterion for temporal arteritis and polymyalgia rheumatica.
- Monitoring response to treatment in temporal arteritis and polymyalgia rheumatica. A clinical response would be expected in two to four days but inflammatory markers normalise over two weeks or longer.
- Used as a component of some clinical indices of rheumatoid arthritis.
- Following the course of patients with rheumatoid arthritis or other connective tissue disorders.
- Screening for tissue infection in specific situations—for example, after orthopaedic surgery or suspected pelvic inflammatory disease—although C reactive protein may be more useful in diagnosis and monitoring response.
- Assessing elderly persons with vague complaints in whom there is a moderate to strong possibility of underlying disease, but no definite findings after history and physical examination.

For those general practices who are served by a laboratory that offers plasma viscosity as a test in preference to ESR.

When should I measure plasma viscosity?

Done under ideal conditions, changes in the ESR and plasma viscosity roughly parallel one another in many but not all situations. Both reflect changes in fibrinogen and/or globulin concentrations. The measurement of viscosity has several advantages. Unlike the ESR, which may be falsely raised as a result of the vagaries of ambient room temperature, age, anaemia, or length of time after specimen collection, plasma viscosity is very reproducible, and is thought to reflect more closely the clinical severity and the efficiency of treatment of a given disease state. In addition, in contrast to the ESR, the normal range is the same for both sexes and for all ages above 3 years. A more detailed comparison of ESR and plasma viscosity will follow in a later question answer set.

GMS contract indicator: none.

URINE CYTOLOGY (LH, JH, AND CAB)

In a laboratory setting, most requests for urine cytology are received from hospital clinics, with primary care specimens forming a minority. The guidance provided is taken mostly from studies of test utility rather than consensus guidance, and relates specifically to the initial primary care investigation of the situation described.

When should I request urine cytology (particularly in the context of microscopic haematuria; MH)?

We recommend urine cytology in patients in the following situations:

- Patients with symptomatic MH.
- Asymptomatic MH in patients > 40 years old or younger patients with risk factors for urological cancer.
- The follow up of patients who have been treated for bladder cancer (in conjunction with urinalysis for MH and other tests if available).
- As a secondary investigation in frank haematuria.

Gross or visible haematuria requires evaluation of the upper and lower urinary tract. Urine cytology has a supportive role in the evaluation of these patients in conjunction with upper tract imaging, cystoscopy, and bladder biopsy. However, in one study, urine cytology did not lead to the discovery of additional tumours that were not detected by other investigations. Recent urinary tract instrumentation should be excluded as a cause of gross haematuria.

MH (by dipstick analysis) is more controversial. Although it is generally accepted that symptomatic MH requires microscopy, this has recently been questioned. There are no reliable data on the incidence of underlying bladder neoplasms in patients with symptomatic MH. Nonetheless, one small study of women who had incontinence and/or irritative voiding and MH showed cytology to be of value, and the American Urological Association (AUA) best practice guidance recommends urine cytology in patients with a history of irritative voiding symptoms. Urine cytology is not helpful in the evaluation of men with lower urinary tract
symptoms because asymptomatic MH is a frequent finding in patients who have benign prostatic hyperplasia, and urine cytology is not an investigation of choice to detect prostatic malignancy. It has not been evaluated in this context.

Urinary tract infection (UTI) does not require investigation with urine cytology, but by microbiological testing. Cytological samples in the setting of UTI may be obscured by polymorphs, and it is sensible to exclude and treat infection before submitting samples for cytological evaluation if indicated in a patient presenting with a UTI.

Asymptomatic MH is common in adult primary care populations (2.3−4.3%), and up to 11% of patients with asymptomatic MH have been reported to have underlying urothelial malignancy. However, in a review of 17 series, comprising a total of 5000 patients, urological cancer was diagnosed in <3% of cases. A Californian study found asymptomatic MH in 2.9% of 20 751 patients, 0.5% of whom had urothelial cancer, yet cancer was also found in 0.5% without MH. Therefore, the authors concluded that the presence of asymptomatic MH was not significantly associated with urological cancer or other serious urological disease. No studies have demonstrated improved outcomes from screening for asymptomatic MH.

Screening for asymptomatic MH cannot be recommended as a means of detecting urological malignancy, but in patients >40 years with an incidental finding of MH, the AUA recommends complete urological evaluation (including cytology). The importance of age as a risk factor is supported by a study in a subspecialised urological setting where 87% of patients in whose samples malignant cells were found were >50 years of age. However, it should be noted that 72% had a history of gross haematuria. The AUA also recommends complete urological evaluation (including cytology) in younger patients with a history that is “suspicious of underlying urological disease”. The relative merits of full urological investigation (including cytology) in younger patients with asymptomatic MH have not been evaluated and are therefore debatable.

A combination of MH and proteinuria in younger patients is a predictor of non-neoplastic primary renal disease. In patients with this combination of findings on dipstick examination, the cytological identification of red blood cell casts and dysmorphic red blood cells may serve as a further indicator of renal parenchymal disease. However, there appear to be differences in laboratory practice as to whether this identifier would form part of microbiology macroscopy/culture examination or whether urine cytology would be expected, because the conventional role of urine cytology is to diagnose malignancy. Primary care organisations should clarify current arrangements in place in their laboratory.

Cytology is advised in patients with risk factors for transitional cell carcinoma, although other screening methods probably have higher combinations of sensitivity and specificity in patients with low grade non-invasive tumours and those with carcinoma in situ. In patients with incidental MH, the risk factors listed by the AUA as indications for urine cytology include: smoking history, occupational exposure to carcinogenic chemicals or dyes (benzenes or aromatic amines), analgesic abuse (for example, phenacetin), cyclophosphamide, and pelvic irradiation.

Known schistosomiasis bladder infection may reasonably be included in relevant populations as a predisposing factor for bladder cancer. Cytology has been used in the follow up of patients who have been treated for bladder cancer in conjunction with testing for MH.

In the laboratory a single cytospin deposit (as opposed to the preparation of duplicate slides) is adequate for cytological evaluation, saves resources, and caused minimal loss of clinically relevant information.

GMS contract indicator: none.

MANAGING URINARY SYMPTOMS [CAMM, AG, AND KGK]

These questions and answers make recommendations about when and how primary care should investigate urinary symptoms. This guidance is based on evidence discussed in detail in Health Protection Agency (www.hpa.org.uk) and PRODIGY (www.prodigy.nhs.uk) guidelines and in the other key references quoted.

When should I send a urine specimen in patients with possible urinary tract infection?

In adults we recommend a urine specimen in:

- Failed antibiotic treatment or persistent symptoms in all individuals.
- Recurrent UTI.
- Suspected pyelonephritis.
- All men with urinary symptoms consistent with infection.
- Catheterised patients with fever ≥38°C, rigors, vomiting, new onset confusion, or costovertebral tenderness (see “In catheterised patients” below).
- Pregnancy:
  - screening for asymptomatic bacteriuria at first antenatal visit
  - investigation of urinary symptoms.
- Anatomical abnormalities of the genitourinary tract.
- Renal impairment.
- Suspected or known immunosuppression—for example, chemotherapy.
- In sexually active men and women with urinary symptoms consider Chlamydia trachomatis infection and send appropriate specimens.

Waiting for the results of urine culture in patients with suspected UTI delays diagnosis and is not cost effective. Conversely, prescribing antibiotics to all patients with urinary symptoms will lead to overuse of antibiotics. Empirical antibiotic treatment in acute, uncomplicated UTI in women should be based on the severity and classic nature of the symptoms and urine dipstick results, with the exception of the specific situations listed in the recommendations above. Submission of a urine specimen before starting treatment may be helpful to identify antibiotic susceptibility, particularly in the event of treatment failure, although it should not delay treatment.

Patients with failed antibiotic treatment or recurrent UTI are more likely to have an infection caused by a bacterium that is resistant to antibiotics. Therefore, urine culture and susceptibility is used to confirm that antibiotic choice is appropriate.

Patients with renal impairment or abnormalities of the genitourinary tract are more likely to have ascending infection/pyelonephritis and antibiotic resistant bacteria, and it is therefore most important to confirm antibiotic susceptibility. Similarly, bacteraemia is much more common in patients with pyelonephritis or fever than in
In children we recommend a urine specimen from:

- **Neonates or infants with:**
  - unexplained fever > 24 hours
  - irritability
  - prolonged neonatal jaundice
  - failure to thrive.
- **Children of any age with:**
  - unexplained fever
  - urinary symptoms
  - vomiting, unexplained abdominal pain, loin pain
  - haematuria, hypertension
  - suspected sexual abuse.

Guidance is based on recommendations of the Royal College of Physicians for the management of acute UTI in children.\(^7\)

Greater opportunities for health gain lie in improving the detection and treatment of acute UTI in children than in the detection and management of vesico–ureteric reflux.\(^7\)

In children we recommend a urine specimen from children with the above signs or symptoms leading to greater detection of UTI.\(^6\) Fever alone can produce pyuria in children,\(^4\) highlighting the need for laboratory diagnosis of infection.

In the elderly we recommend a urine specimen if:

- Dysuria (burning or pain passing urine).
- Fever \(\geq 38^\circ\)C.
- Acute change in continence.

Or:

- **Fever plus one of, new or worsening:**
  - urgency
  - frequency
  - suprapubic pain
  - urinary incontinence
  - gross haematuria.

Do not send urine from elderly patients if:

- Asymptomatic, irrespective of dipstick nitrite/leucocyte results.
- Subacute or chronic non-specific decline in health status as the only symptom because this is a non-specific sign.
- Chronic incontinence without other symptoms.
- Catheterised and asymptomatic patients.

Asymptomatic bacteriuria is extremely common\(^2\) (20% of \(> 65\) year olds and 50% of \(> 80\) year olds or patients with dementia) and is not associated with increased morbidity.\(^2\)

Routine dipstick testing of urine samples for nitrate and leucocytes, and urine culture results in unnecessary antibiotics and treatment of asymptomatic bacteriuria.\(^3\)\(^,\)\(^4\)

In catheterised patients\(^7\)\(^,\)\(^8\) we recommend a urine specimen if:

- Fever or rigors without identified cause.
- New onset delirium or costovertebral tenderness.
- Pre-urological surgery.

Bacteriuria is present in most patients with longterm urinary catheters (\(> 28\) days), but the incidence of fever in longterm catheterised patients is low (approximately one episode/100 days of catheterisation). In 50% of catheterised patients with fever, bacteraemia is present and is caused by ascending urinary infection.\(^5\) In patients with paraplegia, other non-specific symptoms, such as vomiting and increased spasticity, may indicate urinary tract infection.

Antibiotic treatment of asymptomatic bacteriuria in the presence of a catheter does not improve outcome.

When should I use urine dipsticks?

We recommend:

- **Suspected uncomplicated UTI in adults in combination with assessment of clinical symptoms.**
- **Suspected UTI in children, to confirm suspicions of UTI, but a urine specimen should be submitted irrespective of results.**
- **Dipsticks are not reliable in young children (under 2 years).**
- **Dipstick results should always be interpreted in the context of clinical symptoms.**

Testing for leucocytes (leucocyte esterase) and bacteria (nitrite) in combination appears at present to be the best means of dipstick testing.

Positive blood or leucocytes alone can be found in UTI but are also found in the urethral syndrome (urethral inflammation),\(^5\) which does not warrant antibiotic treatment. Nitrite testing alone is not recommended.\(^6\)

A negative nitrite and leucocyte test can often be used to rule out UTI, because it has a reported negative predictive values of up to 95% or above,\(^7\) although reported meta-analysis sensitivity figures are lower (80–90%).\(^8\)\(^,\)\(^9\) These differences probably relate to clinical context. A positive result does not necessarily indicate infection: reported specificity is 60–80%.\(^8\)\(^,\)\(^9\)\(^,\)\(^10\)

Several guidance sources\(^7\)\(^,\)\(^8\)\(^,\)\(^9\)\(^,\)\(^11\) state that subsequent culture in uncomplicated lower UTI in women is not necessary, but stress the need for culture in the other situations listed above. The European Confederation of Laboratory Medicine guidelines recommend a “clinical filter” after the dipstick test is performed, to put the result in the clinical context before decision making.\(^12\) No robust simple algorithms combining symptom scores and dipstick results are available,\(^10\) and there is no clear consensus as to whether urine testing of any form is necessary in all women with possible UTI in view of the usual self limiting course of the disease.\(^13\)

When reading the dipstick test it is important to wait for the time recommended by the manufacturer. Nitrite is produced by the action of bacterial nitrate reductase in urine. Because contact time between bacteria and urine is needed, morning specimens are most reliable.\(^14\) It should also be noted that falsely negative results can be obtained with bacteria that cannot reduce nitrate, such as enterococci. Proteinuria occurs in UTI but is also present in other
conditions and is relatively non-specific. Other diagnoses should be considered for isolated proteinuria.

How should I interpret urine dipstick results?

Figure 1 provides a guideline flowchart of the interpretation of urine dipstick results.

How should I obtain a urine specimen?

We recommend:

- A midstream specimen should be obtained from men, women, and older children. In females, cleaning with water or antiseptic or holding the labia apart does not reduce contamination.100–102
- In toddlers, a potty washed in hot water with washing up liquid is better than a bag urine.103 A urine collection pad in a nappy may be used for infants.104
- Refrigerate specimens to prevent bacterial overgrowth, or use specimen pots containing boric acid.105–107 Because boric acid is antibacterial, specimen pots should be filled to the indicated level to obtain the optimum boric acid concentration.

How should I interpret laboratory results?

We recommend:

- More than $10^5$ organisms/ml (or $>10^5$/litre) of pure growth (single bacterium isolated) obtained from a midstream specimen of urine has historically been considered diagnostic of UTI.
- However, lower counts of pure growth ($10^3$/ml or less), or a mixed growth of two organisms only ($>10^7$/ml) may also indicate UTI in patients with signs and symptoms of UTI.108

Mixed growth from a midstream urine sample usually indicates that the urine has been contaminated on collection by perineal flora; this is often indicated by the presence of epithelial cells on the microscopy report. However, patients with longterm indwelling catheters may have infections with mixed organisms, although is should be emphasised that mixed growth from a cultured specimen of urine does not require antimicrobials in the absence of signs/symptoms of infection.

ACKNOWLEDGEMENTS

We are most grateful to Mrs S Richardson for typing this manuscript and to the following people who are kindly reviewing the group’s work and adding valuable comments in addition to those of the steering group: Professor IS Young (Association of Clinical Biochemists); Dr R Gama and Dr R Herriot (Association of Clinical Pathologists); Dr AJ Mifsud (Association of Medical Microbiologists); Dr MJ Galloway (British Society for Haematology); Dr R Neal and Dr P Hannafor (Royal College of General Practitioners); Dr AB Provan (Royal College of Pathologists); and the other senior officers of these Associations and Colleges who assisted in recruiting reviewers.
REFERENCES


